CLL Trials Open to Recruitment

CI: Professor Peter Hillmen
GA-101 (obinutuzumab) monoclonal Antibody as Consolidation Therapy In CLL: A phase II/III randomised trial in patients with CLL who are in remission following standard chemotherapy.
Funded by CRUK and Roche. Obinutuzumab provided free of charge by Roche.
Sponsor: University of Leeds

CI: Professor Peter Hillmen
Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab: A phase III randomised trial in patients with previously untreated CLL to compare standard therapy with fludarabine, cyclophosphamide and rituximab to ibrutinib plus rituximab.
Funded by CRUK and Janssen. Ibrutinib provided free of charge by Janssen
Sponsor: University of Leeds


CI: Dr Anna Schuh
Single arm NCRI feasibility study of CHOP in combination with ofatumumab, in induction and maintenance for patients with newly diagnosed Richter’s Syndrome
Funded by GlaxoSmithKline – ofatumumab provided free of charge
Sponsor: University of Oxford


CI: Adrian Bloor
Revlimid Early Stage Poor prognosis CLL Trial: A single arm phase II study to investigate the use of Lenalidomide in the treatment of patients with early stage CLL associated with poor prognostic factors
Funded by the Leukaemia Research Fund and Celgene – lenalidomide provided free of charge.
Sponsor: The Christie NHS Foundation Trust

CLL Trials in Set-Up



CI: Professor Andrew Pettitt
A randomised phase II trial of alemtuzumab, dexamethasone and lenalidomide induction followed by lenalidomide maintenance or no further treatment for high risk CLL
Funded by Celgene – lenalidomide provided free of charge
Sponsors: University of Liverpool and Royal Liverpool and Broadgreen University Hospitals NHS Trust


CI: Professor Andrew Pettitt
A Randomised Investigation of Alternative Ofatumumab-based regimens for less fit patients with CLL 
Funded jointly by GlaxoSmithKline and Napp – ofatumumab and bendamustine provided free of charge
Working... Please wait